Strona 4 - Najlepsi lekarze do leczenia raka pęcherza moczowego – TOP 116 lekarzy

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Son Dong Wan, MD, PhD, is the Chief of Urology at Naeun Hospital. He specializes in urologic oncology, urinary incontinence, sexual dysfunction, and laser prostate surgery. He performs robotic and laparoscopic surgery for cancers of the prostate, bladder, ureter, and kidney. He also treats ureteropelvic junction (UPJ) obstruction.

He earned his PhD from Pusan National University. He completed his internship and residency at Pusan National University Hospital. He is a former Chief at Wallace Memorial Baptist Hospital. He served as a Professor at the Catholic University College of Medicine. He was a Clinical Fellow at Seoul National University Bundang Hospital. He was a Visiting Professor at the University of California, San Diego (UCSD). He completed training in urinary incontinence surgery at the University of Liège.

Awards include the Excellent Paper Award (2007) and the Academic Achievement Award (2014) from the Korean Continence Society. He also received the Best Poster Award from the European Association of Urology (2013).

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Urolog, Chirurg

Ordynator Oddziału Urologii Samsung – dr Choi Han Yong specjalizuje się w leczeniu raka pęcherza moczowego w Centrum Medycznym Samsung.

• Onkochirurg koncentrujący się na nowotworach układu moczowego
• Kieruje wiodącym oddziałem urologii
• Doświadczony w zaawansowanych procedurach leczenia raka pęcherza moczowego

Michael Van Kampen to oddany specjalista radioterapii z bogatym doświadczeniem w leczeniu nowotworów urologicznych, takich jak rak pęcherza moczowego.

• Posiada wieloletnią praktykę kliniczną w dziedzinie onkologii radioterapeutycznej
• Stosuje techniki radioterapii celowanej w leczeniu komórek nowotworowych
• Pracuje w specjalistycznej klinice Nordwest we Frankfurcie
• Wchodzi w skład multidyscyplinarnego zespołu zapewniającego kompleksową opiekę onkologiczną

Prof. dr Eduard Becht wnosi 41-letnie doświadczenie urologiczne oraz doktorat honoris causa do swojej pracy w klinice Nordwest. Jego wiedza ekspercka obejmuje szeroki zakres metod: od małoinwazyjnych zabiegów po złożone operacje oszczędzające narządy.

• Specjalizuje się w uroonkologii i urologii rekonstrukcyjnej
• Odznaczony tytułem doktora honoris causa Uniwersytetu Narodowego w Atenach im. Kapodistriasa
• Przewodniczy stowarzyszeniu Interdyscyplinarna Uroonkolgia Frankfurt
• Opublikował ponad 100 prac naukowych na temat schorzeń urologicznych
• Wykłada na Uniwersytecie Goethego we Frankfurcie od 1994 roku

Profesor Gofrit posiada certyfikację do wykonywania operacji robotycznych w leczeniu nowotworów urologicznych. Kieruje Oddziałem Urologii w Centrum Medycznym Hadassah.

• Ukończył specjalistyczne szkolenie z zakresu onkologii urologicznej w Chicago, USA
• Prowadzi badania naukowe i leczy w szczególności nowotwory pęcherza moczowego oraz nerek
• Wykłada chirurgię urologiczną na Uniwersytecie Hebrajskim
• Posiada krajowe i międzynarodowe nagrody za osiągnięcia w dziedzinie urologii
• Specjalizuje się w chirurgii endoskopowej oraz operacjach z użyciem robota da Vinci

Dr Yutkin posiada ponad 20-letnie doświadczenie w diagnostyce i leczeniu w Centrum Medycznym Hadassah.

• Ukończył Wydział Medyczny Uniwersytetu Hebrajskiego w Jerozolimie
• Specjalizuje się w zaburzeniach stawu skroniowo-żuchwowego
• Biegle posługuje się językiem angielskim, hebrajskim i rosyjskim

Specjalista urologii onkologicznej — koncentruje się wyłącznie na leczeniu raka pęcherza moczowego w Centrum Medycznym Assuta.

• Urolog posiadający bogate doświadczenie w leczeniu raka pęcherza moczowego.
• Pracuje w Centrum Medycznym Assuta — wiodącej placówce onkologicznej.
• Dedykuje swoją praktykę onkourologii, zapewniając specjalistyczną opiekę medyczną.

Radioterapeuta specjalizujący się w leczeniu raka pęcherza moczowego w Centrum Medycznym Assuta.

• Specjalizuje się w radioterapii
• Posiada doświadczenie w leczeniu różnych schorzeń onkologicznych
• Stosuje metody leczenia oparte na faktach (EBM)

Prof. Jablonski-Perec szkoliła się w Sloan-Kettering Cancer Center – jednej z czołowych instytucji onkologicznych na świecie. Obecnie kieruje Instytutem Onkologii w Centrum Medycznym Hadassah.

• Kieruje Centrum Leczenia Raka Piersi od 1998 roku
• Jest profesorem onkologii na Uniwersytecie Hebrajskim
• Należy do kilku międzynarodowych stowarzyszeń onkologicznych
• Otrzymała stypendium Wydziału Medycznego Hadassah